Castleman’s disease is a lymphoproliferative disorder characterized by atypical hyperplasia of the lymph nodes and systemic symptoms; can also affect the skin and the blood is important.
This condition is categorized by the level of engagement (unicentric or multicentric) and lymph node pathology observed (hyaline-vascular, plasma cell or mixed cellularity). Pathogenesis also has a role in the classification and treatment of multicentric Castleman’s disease; This variant can either be associated with the presence of human herpesvirus-8 (HHV-8) infection or associated with POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) syndrome, or idiopathic.
The main cytokines that are responsible for causing idiopathic multicentric Castleman disease (IMCD) is interleukin-6 (IL-6). Therefore, treatment with agents that bind to IL-6 (as siltuximab) or blocking IL-6 receptor (such as tocilizumab) have been used. We report a woman with IMCD were successfully treated with siltuximab; and his skin manifestations of systemic disease (lung and lymph nodes) improved within three months. However, nine months after the start siltuximab, he developed a cough worsened and new infiltrates in the right lung on positron emission tomography / computed tomography (PET / CT) scans; no other constitutional symptoms such as fever, night sweats and fatigue. Diagnosis including Castleman disease recurrence, lung neoplasm and infection.
Symptoms of pulmonary infiltrates on scanning resolved after treatment with systemic levofloxacin, showed that he had a fever pneumonia antibiotic sensitive. We found her therapy siltuximab blocked fever and constitutional symptoms associated IL-6 which is usually the hallmark of pneumonia. Therefore, patients who received the drug as siltuximab and tocilizumab that blocks IL-6 pathway and damage the acute phase inflammatory response may fail for real constitutional symptoms such as fever when infected.
Afebrile Pneumonia in a Patient With Multicentric Castleman Disease on Siltuximab: Infection Without Fever on Anti-Interleukin-6 Therapy
Anti-infective drugs furazolidone inhibits NF-kB signaling and induces apoptosis of cancer cells small cell lung
Targeting the nuclear factor kappa B (NF-kB) signaling pathway has been a promising strategy for the development of new antitumor drugs. In this paper, we found that anti-infective drug furazolidone (FZD) could significantly inhibit NF-kB-driven luciferase activity, and real FZD could inhibit both the constitutive and tumor necrosis factor-α (TNF) -triggered phosphorylation of NF kB p65 cancer small cell lung (SCLC). Further research revealed that FZD inhibitor inhibits the expression of kappa B kinase β (IKKβ) in SCLC cells.
In addition, we found that the FZD has significant antitumor activity in SCLC cells. Real FZD can suppress cell viability SCLC cells dose dependence, and FZD could significantly induce cleavage of poly ADP-ribose polymerase (PARP) and Caspase3, biomarkers of apoptosis, in SCLC cells. Flow cytometry was also revealed that the FZD induced apoptosis in SCLC cells.
Finally, we also found that overexpression of constitutively activated IKKβ can significantly eliminate the FZD-induced inhibition of cell growth in SCLC cells, which further confirms that the FZD shown anticancer activity of SCLC via regulate NF-kB signaling pathway
Description: The IL-17 family is comprised of at least six proinflammatory cytokines that share a conserved cysteine-knot structure but diverge at the N-terminus. IL-17 family members are glycoproteins secreted as dimers that induce local cytokine production and recruit granulocytes to sites of inflammation. IL-17 is induced by IL-15 and IL-23, mainly in activated CD4+ T cells distinct from Th1 or Th2 cells. IL-17F is the most homologous to IL-17, but is induced only by IL-23 in activated monocytes. IL-17B binds the IL-17B receptor, but not the IL-17 receptor; it is most homologous with IL-17D, which is expressed by resting CD4+ T cells and CD19+ B cells. IL-17E is mainly produced by Th2 cells and recruits eosinophils to lung tissue. IL-17C has a very restricted expression pattern but has been detected in adult prostate and fetal kidney libraries.
Description: Cytokines are small, soluble proteins with pleiotropic effects on a variety of cell types. Cytokines have a regulatory function over the immune system and mediate aspects of inflammatory response. They exert their biological effects through the binding of membrane-bound receptors which, in turn, initiate signal transduction cascades and elicit physiological changes in their target cell. Interleukin-17 (IL-17) and its cognate receptor, IL-17R, are an example of such a cytokine receptor pair. Originally identified as a rodent cDNA termed CTLA8, IL-17 is capable of inducing the secretion of IL-6 and IL-8 and augmenting the expression of ICAM-1 in human fibroblast cultures. The IL-17 protein exhibits a striking degree of homology with the HSV13 protein which mimics its function. The IL-17 receptor is a type I transmembrane protein 864 amino acids in length, that is highly expressed in spleen and kidney.
Description: IL-17 binds to IL-17 receptors (IL-17 R), which share no homology with any known family of receptors. While the expression of IL-17 is restricted to activated T cells, IL-17 R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested. The amino acid sequence of human IL-17 R is 69% identical to mouse IL-17 R.
Description: The IL-17 family is comprised of at least six proinflammatory cytokines that share a conserved cysteine-knot structure but diverge at the N-terminus. IL-17 family members are glycoproteins secreted as dimers that induce local cytokine production and recruit granulocytes to sites of inflammation. IL-17 is induced by IL-15 and IL-23, mainly in activated CD4+ T cells distinct from Th1 or Th2 cells. IL-17F is the most homologous to IL-17, but is induced only by IL-23 in activated monocytes. IL-17B binds the IL-17B receptor, but not the IL-17 receptor; it is most homologous with IL-17D, which is expressed by resting CD4+ T cells and CD19+ B cells. IL-17E is mainly produced by Th2 cells and recruits eosinophils to lung tissue. IL-17C has a very restricted expression pattern but has been detected in adult prostate and fetal kidney libraries.
Description: Fully biologically active when compared to standard. The ED50 as determined by inducing IL-6 secretion of murine NIH/3T3 cells is less than 7.5 ng/ml, corresponding to a specific activity of > 1.3 × 105 IU/mg.
Description: Interleukin-17A Human Recombinant produced in E.Coli is a homodimeric, non-glycosylated polypeptide chain containing a total of 264 amino acids (2 chains of 132 aa) and having a molecular mass of 31kDa. ;The IL-17 is purified by proprietary chromatographic techniques.
Description: The originally described IL-17 protein, now known as IL-17A, is a homodimer of two 136 amino acid chains, secreted by activated T-cells that act on stromal cells to induce production of proinflammatory and hematopoietic bioactive molecules. Today, IL-17 represents a family of structurally-related cytokines that share a highly conserved C-terminal region but differ from one another in their N-terminal regions and in their distinct biological roles. The six known members of this family, IL-17A through IL-17F, are secreted as homodimers. IL-17A exhibits cross-species bioactivity between human and murine cells. Recombinant human IL-17A is a 31.3 kDa disulfide-linked homodimer of two 137 amino acid polypeptide chains.
Description: The IL-17 family is comprised of at least six proinflammatory cytokines that share a conserved cysteine-knot structure but diverge at the N-terminus. IL-17 family members are glycoproteins secreted as dimers that induce local cytokine production and recruit granulocytes to sites of inflammation. IL-17 is induced by IL-15 and IL-23, mainly in activated CD4+ T cells distinct from Th1 or Th2 cells. IL-17F is the most homologous to IL-17, but is induced only by IL-23 in activated monocytes. IL-17B binds the IL-17B receptor, but not the IL-17 receptor; it is most homologous with IL-17D, which is expressed by resting CD4+ T cells and CD19+ B cells. IL-17E is mainly produced by Th2 cells and recruits eosinophils to lung tissue. IL-17C has a very restricted expression pattern but has been detected in adult prostate and fetal kidney libraries.
Description: IL-17 Human Recombinant produced in HEK cells is a glycosylated homodimer, having a molecular weight range of 30-35kDa due to glycosylation.;The IL-17 is purified by proprietary chromatographic techniques.
Description: IL-17 binds to IL-17 receptors (IL-17 R), which share no homology with any known family of receptors. While the expression of IL-17 is restricted to activated T cells, IL-17 R mRNA exhibits a broad tissue distribution, and has been detected in virtually all cells and tissues tested. The amino acid sequence of human IL-17 R is 69% identical to mouse IL-17 R.
Description: IL-17 Antibody: Interleukin 17 (IL-17) is a family of pro-inflammatory cytokines produced by activated T cells and is thought to have a major role in the initiation and perpetuation of rheumatoid arthritis. IL-17 regulates the activities of NF-κB and mitogen-activated protein kinases such as ERK and JNK. In addition, IL-17 stimulates the expression of IL-6 and cyclooxygenase-2 and enhances the production of nitric oxide. IL-17-producing T helper cells (TH-17 cells) have been the subject of much attention due to the importance of IL-17 in the pathogenesis of autoimmune inflammation. Because of its role in autoimmune diseases, it is thought that targeting the production and action of IL-17 would be beneficial therapeutically in these diseases.
Description: IL-17 Antibody: Interleukin 17 (IL-17) is a family of pro-inflammatory cytokines produced by activated T cells and is thought to have a major role in the initiation and perpetuation of rheumatoid arthritis. IL-17 regulates the activities of NF-κB and mitogen-activated protein kinases such as ERK and JNK. In addition, IL-17 stimulates the expression of IL-6 and cyclooxygenase-2 and enhances the production of nitric oxide. IL-17-producing T helper cells (TH-17 cells) have been the subject of much attention due to the importance of IL-17 in the pathogenesis of autoimmune inflammation. Because of its role in autoimmune diseases, it is thought that targeting the production and action of IL-17 would be beneficial therapeutically in these diseases.
Description: IL-17 Antibody: Interleukin 17 (IL-17) is a family of pro-inflammatory cytokines produced by activated T cells and is thought to have a major role in the initiation and perpetuation of rheumatoid arthritis. IL-17 regulates the activities of NF-κB and mitogen-activated protein kinases such as ERK and JNK. In addition, IL-17 stimulates the expression of IL-6 and cyclooxygenase-2 and enhances the production of nitric oxide. IL-17-producing T helper cells (TH-17 cells) have been the subject of much attention due to the importance of IL-17 in the pathogenesis of autoimmune inflammation. Because of its role in autoimmune diseases, it is thought that targeting the production and action of IL-17 would be beneficial therapeutically in these diseases.
Description: IL-17 Antibody: Interleukin 17 (IL-17) is a family of pro-inflammatory cytokines produced by activated T cells and is thought to have a major role in the initiation and perpetuation of rheumatoid arthritis. IL-17 regulates the activities of NF-κB and mitogen-activated protein kinases such as ERK and JNK. In addition, IL-17 stimulates the expression of IL-6 and cyclooxygenase-2 and enhances the production of nitric oxide. IL-17-producing T helper cells (TH-17 cells) have been the subject of much attention due to the importance of IL-17 in the pathogenesis of autoimmune inflammation. Because of its role in autoimmune diseases, it is thought that targeting the production and action of IL-17 would be beneficial therapeutically in these diseases.
Description: The protein encoded by this gene is a proinflammatory cytokine produced by activated T cells. This cytokine regulates the activities of NF-kappaB and mitogen-activated protein kinases. This cytokine can stimulate the expression of IL6 and cyclooxygenase-2 (PTGS2/COX-2), as well as enhance the production of nitric oxide (NO). High levels of this cytokine are associated with several chronic inflammatory diseases including rheumatoid arthritis, psoriasis and multiple sclerosis.
Description: Quantitative sandwich ELISA for measuring Human IL-17 in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human IL-17 in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Quantitative sandwich ELISA for measuring Human IL-17 in samples from cell culture supernatants, serum, whole blood, plasma and other biological fluids.
Description: Interleukin-17A Human Recombinant produced in E.Coli is a single, non-glycosylated, Polypeptide chain containing 132 amino acids fragment (24-155) having a molecular weight of 19.62kDa and fused with a 4.5kDa amino-terminal hexahistidine tag. ;The IL-17A His is purified by proprietary chromatographic techniques.
Description: Quantitativesandwich ELISA kit for measuring Human Interleukin 17A (IL-17A/IL-17) in samples from serum, urine, cell culture supernates, tissue homogenates. A new trial version of the kit, which allows you to test the kit in your application at a reasonable price.
Description: Quantitativesandwich ELISA kit for measuring Human Interleukin 17A (IL-17A/IL-17) in samples from serum, urine, cell culture supernates, tissue homogenates. Now available in a cost efficient pack of 5 plates of 96 wells each, conveniently packed along with the other reagents in 5 separate kits.
Description: Human IL17RA&IL17RC Protein, Fc Tag&Fc Tag (ILC-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 33 - Trp 320 (IL-17RA) & Leu 21 - His 465 (IL-17RC) (Accession # Q96F46-1 (IL-17RA) & NP_703190.1 (IL-17RC)).
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IL-17 . This antibody is tested and proven to work in the following applications:
Description: A polyclonal antibody raised in Rabbit that recognizes and binds to Human IL-17 . This antibody is tested and proven to work in the following applications:
Description: Human IL-17 RA Protein, Fc Tag (ILA-H5257) is expressed from human 293 cells (HEK293). It contains AA Leu 33 - Trp 320 (Accession # Q96F46-1).
In total, 210 patients were enrolled, with 19 different patterns (groups of pharmacological alone or in combination) of the prescribed treatment. Most patients begin their treatment with conventional synthetic (cs) DMARD alone or in combination with a glucocorticosteroid.
Chris
